Olema Pharmaceuticals (OLMA) EBITDA (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of EBITDA data on file, last reported at -$58.0 million in Q1 2026.

• On a quarterly basis, EBITDA fell 66.28% year-over-year to -$58.0 million in Q1 2026; TTM through Mar 2026 was -$201.8 million, a 41.33% decrease from a year earlier, with the FY2025 full-year figure at -$178.7 million, down 25.62% from the prior year.
• EBITDA for Q1 2026 stood at -$58.0 million, down from -$50.1 million in the prior quarter.
• Over the last five years, EBITDA for OLMA reached as high as -$21.6 million in Q2 2023 and fell as low as -$58.0 million in Q1 2026.
• Historically, EBITDA has averaged -$34.8 million across 5 years, with a median of -$33.5 million in 2024.
• Across the five-year window, EBITDA tumbled 101.51% in 2022 and surged 35.12% in 2023, its largest moves.
• Year by year, EBITDA stood at -$27.2 million in 2022, then declined by 11.75% to -$30.4 million in 2023, then slipped by 20.88% to -$36.8 million in 2024, then tumbled by 36.22% to -$50.1 million in 2025, then retreated by 15.78% to -$58.0 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$58.0 million in Q1 2026, -$50.1 million in Q4 2025, and -$45.9 million in Q3 2025.